HONG KONG--(Marketwire -06/20/12)- Today, www.EquityLeader.com introduced research coverage of Sanofi SA (ADR) (SNY) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA). Full research reports are available to readers at: www.EquityLeader.com/index.php?sm1=SNY&sm2=TEVA.
With markets in correction mode, investors are looking to quantify an accurate model, weighing positives and negatives of the months ahead. Upcoming negative pressures include China's slowdown, the European recession, the end of the Fed's Operation Twist stimulus program, continued geopolitical risks, election uncertainty, and potential 2013 budget bombshell of tax hikes and spending cuts. Meanwhile, positive offsets are driven by central banks (particularly China) cutting rather than hiking rates, deceleration in fuel and food prices, increase in consumer sentiment and resulting retail sales, signs of improvement in housing sales and new strength in auto production schedules.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Equity Leader has decided to cover Sanofi SA (ADR) for its current position within the healthcare industry. Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health. A copy of this report detailing Sanofi SA (ADR) (SNY) is available at: www.EquityLeader.com/index.php?sm1=SNY.
Equity Leader is also taking note of Teva Pharmaceutical Industries Ltd (ADR) for its changing role within the healthcare industry. Teva Pharmaceutical Industries Ltd (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. To download free research on Teva Pharmaceutical Industries Ltd (ADR) (TEVA) investors may visit: www.EquityLeader.com/index.php?sm2=TEVA.
About Equity Leader
Whether you are a first time investor or seasoned market professional, Equity Leader provides the resources necessary to simplify your research process. Our focus has always been to empower investors with the information they need to make their own investment decisions.